<DOC>
	<DOCNO>NCT00004401</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine safety human botulism immune globulin ( BIG ) patient infant botulism monitor side effect ( e.g. , rash , fever , hypotension , anaphylaxis ) . II . Assess efficacy BIG patient monitor disease severity , incidence complication ( respiratory arrest , aspiration , pneumonia , etc . ) , length hospital stay .</brief_summary>
	<brief_title>Study Human Botulism Immunoglobulin Infants With Botulism</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This open label , multicenter study . Patients begin therapy within 72 hour hospital admission , may receive human botulism immunoglobulin ( BIG ) certain circumstance 72 hour . Patients receive ( BIG ) IV . Patients monitor side effect , disease severity , complication , length hospital stay . Patients follow 2 week treatment , every 4 week 6 month . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Botulism</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Clinical diagnosis infant botulism previously healthy infant Bulbar palsy Constipated Lethargy Diminished head control Poor feed Generalized weakness hypotonia Weak cry Afebrile ( unless secondary infection present ) Subacute acute onset Normal electrolytes Any patient eligible provide treatment available lifethreatening condition</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>March 2000</verification_date>
	<keyword>bacterial infection</keyword>
	<keyword>clostridium infection</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>infant botulism</keyword>
	<keyword>rare disease</keyword>
</DOC>